Interleukin-1 receptor antagonist attenuates cyclophosphamide-induced mucositis in a murine model

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 6, 2011, Pages 1445-1453

  Xiang, Di ^a   Guo, Yiping ^a   Zhang, Jing ^a   Gao, Jin ^a   Lu, Huili ^a   Zhu, Shunying ^a   Wu, Mingyuan ^a   Yu, Yan ^a   Han, Wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Chemotherapy; Cyclophosphamide; Mucositis; Recombinant human interleukin 1 receptor antagonist

Indexed keywords

CYCLOPHOSPHAMIDE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; FEMALE; HISTOPATHOLOGY; INTESTINE INJURY; MALE; MORTALITY; MOUSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BODY WEIGHT; CYCLOPHOSPHAMIDE; HUMANS; INTESTINAL MUCOSA; MICE; MICE, INBRED BALB C; MUCOSITIS; PEPTIDE FRAGMENTS; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS;

EID: 79959613453     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1439-1     Document Type: Article

References (44)

1. DeVita VT Jr, Chu E (2008) A history of cancer chemotherapy. Cancer Res 68(21):8643-8653
2. Khan SA, Wingard JR (2001) Infection and mucosal injury in cancer treatment. J Natl Cancer Inst Monogr 29:31-36
3. Duncan M, Grant G (2003) Oral and intestinal mucositis - causes and possible treatments. Aliment Pharmacol Ther 18(9):853-874 (Pubitemid 37346671)
4. Chudgar UH, Rundus CH, Peterson VM (1995) Recombinant human interleukin-1 receptor antagonist protects early myeloid progenitors in a murine model of cyclophosphamide-induced myelotoxicity. Blood 85(9):2393-2401
5. Wright DE, Cheshier SH, Wagers AJ, Randall TD, Christensen JL, Weissman IL (2001) Cyclophosphamide/granulocyte colony-stimulating factor causes selective mobilization of bone marrow hematopoietic stem cells into the blood after m phase of the cell cycle. Blood 97(8):2278-2285 (Pubitemid 32291472)
6. Shanafelt TD, Lin T, Geyer SM, Zent CS, Leung N, Kabat B, Bowen D, Grever MR, Byrd JC, Kay NE (2007) Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 109(11):2291-2298 (Pubitemid 46801560)
7. Dong Q, Barsky D, Colvin ME, Melius CF, Ludeman SM, Moravek JF, Colvin OM, Bigner DD, Modrich P, Friedman HS (1995) A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5′-d(gac). Proc Natl Acad Sci USA 92(26):12170-12174
8. Rodriguez-Antona C, Ingelman-Sundberg M (2006) Cytochrome p450 pharmacogenetics and cancer. Oncogene 25(11):1679-1691
9. Moreb J, Zucali JR, Zhang Y, Colvin MO, Gross MA (1992) Role of aldehyde dehydrogenase in the protection of hematopoietic progenitor cells from 4-hydroperoxycyclophosphamide by interleukin 1 beta and tumor necrosis factor. Cancer Res 52(7):1770-1774
10. Jones RJ, Barber JP, Vala MS, Collector MI, Kaufmann SH, Ludeman SM, Colvin OM, Hilton J (1995) Assessment of aldehyde dehydrogenase in viable cells. Blood 85(10):2742-2746
11. Storms RW, Trujillo AP, Springer JB, Shah L, Colvin OM, Ludeman SM, Smith C (1999) Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci USA 96(16):9118-9123 (Pubitemid 29374717)
12. Ijiri K, Potten CS (1987) Further studies on the response of intestinal crypt cells of different hierarchical status to eighteen different cytotoxic agents. Br J Cancer 55(2):113-123 (Pubitemid 17021671)
13. Niscola P, Romani C, Cupelli L, Scaramucci L, Tendas A, Dentamaro T, Amadori S, de Fabritiis P (2007) Mucositis in patients with hematologic malignancies: an overview. Haematologica 92(2):222-231
14. Sonis ST (2004) The pathobiology of mucositis. Nat Rev Cancer 4(4):277-284
15. Benson AB 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22(14):2918-2926 (Pubitemid 41079912)
16. Gibson RJ, Stringer AM (2009) Chemotherapy-induced diarrhoea. Curr Opin Support Palliat Care 3(1):31-35
17. Viele CS (2003) Overview of chemotherapy-induced diarrhea. Semin Oncol Nurs 19(4 Suppl 3):2-5
18. Hancock SL, Chung RT, Cox RS, Kallman RF (1991) Interleukin 1 beta initially sensitizes and subsequently protects murine intestinal stem cells exposed to photon radiation. Cancer Res 51(9):2280-2285
19. Gibson RJ, Keefe DM, Thompson FM, Clarke JM, Goland GJ, Cummins AG (2002) Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 47(12):2751-2757 (Pubitemid 35471617)
20. Cao S, Black JD, Troutt AB, Rustum YM (1998) Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model. Cancer Res 58(15):3270-3274 (Pubitemid 28371064)
21. Kim KA, Zhao J, Andarmani S, Kakitani M, Oshima T, Binnerts ME, Abo A, Tomizuka K, Funk WD (2006) R-spondin proteins: a novel link to beta-catenin activation. Cell Cycle 5(1):23-26
22. Booth D, Haley JD, Bruskin AM, Potten CS (2000) Transforming growth factor-b3 protects murine small intestinal crypt stem cells and animal survival after irradiation, possibly by reducing stem-cell cycling. Int J Cancer 86(1):53-59 (Pubitemid 30133986)
23. Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL, Yin S, Hill DC, Wiemann B, Starnes CO, Havill AM, Lu ZN, Aukerman SL, Pierce GF, Thomason A, Potten CS, Ulich TR, Lacey DL (1998) Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 58(5):933-939 (Pubitemid 28182461)
24. Stein A, Voigt W, Jordan K (2009) Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 0:1-13
25. Sutherland DB, Varilek GW, Neil GA (1994) Identification and characterization of the rat intestinal epithelial cell (iec-18) interleukin-1 receptor. Am J Physiol 266(5 Pt 1):C1198-C1203
26. Johnson CS, Keckler DJ, Topper MI, Braunschweiger PG, Furmanski P (1989) In vivo hematopoietic effects of recombinant interleukin-1 alpha in mice: stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood 73(3):678-683
27. Neta R, Sztein MB, Oppenheim JJ, Gillis S, Douches SD (1987) The in vivo effects of interleukin. 1. I Bone marrow cells are induced to cycle after administration of interleukin 1. J Immunol 139(6):1861-1866 (Pubitemid 17141615)
28. Moore MA, Warren DJ (1987) Synergy of interleukin 1 and granulocyte colony-stimulating factor: in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice. Proc Natl Acad Sci USA 84(20):7134-7138 (Pubitemid 18017322)
29. Gasparetto C, Laver J, Abboud M, Gillio A, Smith C, O'Reilly RJ, Moore MA (1989) Effects of interleukin-1 on hematopoietic progenitors: evidence of stimulatory and inhibitory activities in a primate model. Blood 74(2):547-550 (Pubitemid 19208791)
30. Andus T, Daig R, Vogl D, Aschenbrenner E, Lock G, Hollerbach S, Kollinger M, Scholmerich J, Gross V (1997) Imbalance of the interleukin 1 system in colonic mucosa-association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2. Gut 41(5):651-657 (Pubitemid 27496145)
31. Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, Armes LG, Sommer A, Eisenberg SP, Thompson RC (1990) Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343(6256):336-340 (Pubitemid 120028524)
32. Zhang J, Xiang D, Zhu S, Mao W, Lu H, Wu M, Wang Q, Yu Y, Herbst KD, Han W (2009) Interleukin 1 receptor antagonist inhibits normal hematopoiesis and reduces lethality and bone marrow toxicity of 5-fluouracil in mouse. Biomed Pharmacother 63(7):501-508
33. Daig R, Rogler G, Aschenbrenner E, Vogl D, Falk W, Gross V, Scholmerich J, Andus T (2000) Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6. Gut 46(3):350-358 (Pubitemid 30313386)
34. Nakai S, Mizuno K, Kaneta M, Hirai Y (1988) A simple, sensitive bioassay for the detection of interleukin-1 using human melanoma a375 cell line. Biochem Biophys Res Commun 154(3):1189-1196
35. Xiang D, Zhang J, Chen Y, Guo Y, Schalow A, Zhang Z, Hu X, Yu H, Zhao M, Zhu S, Lu H, Wu M, Yu Y, Moldenhauer A, Han W (2009) Expressions and purification of a mature form of recombinant human chemerin in escherichia coli. Protein Expr Purif 69(2):153-158
36. Kirisawa R, Fukuda T, Yamanaka H, Hagiwara K, Goto M, Obata Y, Yoshino T, Iwai H (1998) Enzymatic amplification and expression of bovine interleukin-1 receptor antagonist cdna. Vet Immunol Immunopathol 62(3):197-208 (Pubitemid 28228565)
37. Siegmund B, Lehr HA, Fantuzzi G, Dinarello CA (2001) Il-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci USA 98(23):13249-13254 (Pubitemid 33051348)
38. Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS, Davis TW, Masferrer JL (2002) Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of cpt-11. Cancer Res 62(20):5778-5784 (Pubitemid 35204735)
39. Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN (1970) Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Arch Surg 101(4):478-483
40. Russo JE, Hilton J, Colvin OM (1989) The role of aldehyde dehydrogenase isozymes in cellular resistance to the alkylating agent cyclophosphamide. Prog Clin Biol Res 290:65-79
41. Moore JV (1985) Clonogenic response of cells of murine intestinal crypts to 12 cytotoxic drugs. Cancer Chemother Pharmacol 15(1):11-15
42. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A (1994) P27kip1, a cyclin-cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8(1):9-22
43. Granowitz EV, Porat R, Mier JW, Pribble JP, Stiles DM, Bloedow DC, Catalano MA, Wolff SM, Dinarello CA (1992) Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 4(5):353-360
44. Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, Modafferi D, Zhou L, Bell D, Appleton B (2006) Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65(8):1006-1012 (Pubitemid 44133261)